Palbociclib trials for HR+/HER2- Breast Cancer

All Palbociclib trials · All HR+/HER2- Breast Cancer trials

Phase breakdown

Recruiting trials studying Palbociclib for HR+/HER2- Breast Cancer

• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
  NCT06805812 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations

Common questions

How many trials study Palbociclib for HR+/HER2- Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.